Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin
- 24 January 2011
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 83 (3) , 419-427
Abstract
Previous reports demonstrated that amino acid (aa) substitutions in the hepatitis C virus (HCV) core protein are predictors of non-virological responses to pegylated interferon (Peg-IFN) and ribavirin combination therapy. The aim of this study was to investigate the impact of core aa substitutions on viral kinetics during the treatment and relapse after the treatment. The 187 patients with HCV genotype 1 enrolled in this study were categorized into four groups according to core aa substitution patterns: double-wild group (n = 92), Arg70/Leu91; 70-mutant group (n = 42), Gln70/Leu91; 91-mutant group (n = 31), Arg70/Met91; and double-mutant group (n = 22), Gln70/Met91. The relationship between the core aa substitutions and the virological response was examined. Multivariate logistic regression analyses showed that substitution at aa 70 was significantly associated with a poor virological response during the first 12 weeks (decline of <1 log from baseline at week 4, <2 log at week 12), and substitution at aa 91 was significantly associated with detectable HCV RNA at week 24. With respect to relapse, only the ribavirin exposure (odds ratio (OR), 0.77; 95% confidence interval (CI), 0.60–0.98) and HCV RNA disappearance between weeks 13 and 24 (OR, 23.69; 95% CI, 5.44–103.08) were associated independently with relapse, with no correlation being found with the core aa substitutions and relapse. In conclusion, the results showed that core aa substitutions can be strong predictive factors at pretreatment of the non-response, but not for relapse, for virological responders with HCV RNA disappearance during treatment. J. Med. Virol. 83:419–427, 2011.Keywords
This publication has 44 references indexed in Scilit:
- Ribavirin dose reduction raises relapse rate dose‐dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha‐2b plus ribavirinJournal of Viral Hepatitis, 2009
- Pegylated interferon alpha‐2b (Peg‐IFN α‐2b) affects early virologic response dose‐dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg‐IFN α‐2b plus ribavirinJournal of Viral Hepatitis, 2009
- Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factorsHepatology, 2008
- Proteasome Activation by Hepatitis C Core Protein Is Reversed by Ethanol-Induced Oxidative StressGastroenterology, 2008
- DDX3 DEAD-Box RNA Helicase Is Required for Hepatitis C Virus RNA ReplicationJournal of Virology, 2007
- Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to TherapyJournal of Virology, 2007
- Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative StressJournal of Virology, 2007
- Hepatitis C Virus Core Protein Blocks Interferon Signaling by Interaction with the STAT1 SH2 DomainJournal of Virology, 2006
- Hepatitis C Virus Core Protein Suppresses NF-κB Activation and Cyclooxygenase-2 Expression by Direct Interaction with IκB Kinase βJournal of Virology, 2005
- An Algorithm for the Grading of Activity in Chronic Hepatitis CHepatology, 1996